Cinda BioOX40 monoclonal antibody (IBI101) has been approved by FDA-issued drug clinical trials

today, Cinda Bio
Pharmaceutical(http://(Hong Kong Stock Exchange Code: 01801) announced that it has developed a recombinant whole-human source anti-tumor necrosis receptor hyperfamily member 4 (OX40) monoclonal antibody (iBI101) monoclonal antibody (iBI101 http://
) and has beendrug http://(
) by the u.SFood
and drug(http:// http://
) (
)approvals are intended to conduct clinical studies in patients with advanced solid tumorsIBI101 is the third clinical research(http://of a
clinical study approved by the U.SFood and Drug Administration for drug clinical trials after Sinda Bio iBI308 (Sindili monoantigen, anti-PD-1 monoclonal antibody), IBI188 (anti-CD47 monoclonal antibody antibody), and the first anti-OX40 monoclonal antibody drug in China to obtain a clinical trial approval in the United Stateson IBI101injectable recombinant whole human-sourced anti-tumor necrosis factor receptor hyperfamily member 4 (OX40) monoclonal antibody (research code IBI101), an INDEPENDENTly owned OX40 agonist developed by Cinda Biopharma, intended to treat a wide range of physical tumor diseasespreclinical research data confirm that iBI101 action mechanism is clear, can significantly enhance the effect of T-cell activation, and mediate the elimination of regulated T-cells, thereby playing a role in inhibiting tumor cell growthIBI101 has a stronger activation of T-cell capabilities and anti-tumor effects than exposed target antibodiesTHE OX40 AGONIST IS EXPECTED TO EXPAND INTO MORE UNSATISFIED CANCER TREATMENT AREAS WITH

(HTTP://WWW.CHEMDRUG.COM/COMPANY/)
ANTI-PD-1 MONOCLONAL ANTIBODY SINDILLI MONOANTIGEN (RESEARCH CODE: IBI308) AND OTHER DRUGS IN THE DEVELOPMENT PIPELINE